• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Informed Consent: An Ongoing Process for Focused Care

Informed Consent: An Ongoing Process for Focused Care

May 1, 2018
Joshua Feder, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Josh Feder, MD Child and family psychiatrist, Solana Beach, CA, Editor-in-Chief of the Carlat Child Psychiatry Report Dr. Feder has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Informed consent is a foundation for good clinical practice and can provide legal protection. But informed consent is more than defensive medicine. It is a vehicle for framing good care.

How often do people use the consent process? Malpractice companies recommend that the patient (or parent) sign consent whenever a medication is started. This might be a new page in the record or initialing an amendment to a more permanent form. Here is a link to a sample of an informed consent form. Some clinics build informed consent into the electronic health record (EHR) or paperwork. Do you spend time on it, or do you just get the signature?

The scant research available suggests that—at least among internists and family practice providers—the depth of the informed consent discussion is quite limited (Braddock CH et al, J Gen Intern Med 1997;12(6):339–345).

Lawsuits against child psychiatrists often focus on poor medication outcomes (Psychiatry-Edgmont 2009;6(8):38–39), and the absence of good documentation of informed consent can lead to awards and even charges of battery. The California Medical Board regularly reports actions taken when consent is absent (see: http://www.mbc.ca.gov).

But the informed consent process also helps us organize care. At every follow-up appointment, we should review medications in the context of the overall treatment plan, in continual family guidance. The elements of informed consent can foster a climate of collaboration and should include the following:

Demographic information: Like every other page in a chart, the informed consent form should have the patient’s name, the patient’s date of birth, and the dates of all entries.

Diagnoses: DSM and ICD-10 diagnoses are a limited reflection of a patient’s actual situation. Still, list relevant diagnoses and other important medical conditions (eg, neurological, gastrointestinal, respiratory), as well as important V-code circumstances such as recent moves, divorce, or school problems. These impact the patient’s presentation and are relevant to the overall treatment plan.

Target symptoms: In child psychiatry, it is usually more relevant to focus on target symptoms than diagnoses. I work with families to prioritize target symptoms so that we focus on issues important to them while keeping in mind good medical approaches. For instance, a family may worry about their teen’s depressed feelings while you might place the patient’s alcohol use on par, in which case you would explain to the family that the teen’s alcohol use will need to be addressed to treat the depression.

Treatment protocol: Lay out the specific plan for medication, including medication name(s), dosage, timing, and additional information such as plans for titration. Make clear what the family needs to do.

Alternative treatments: List the other medications or treatments discussed. For example, when considering inattention or impulsivity, you might have talked about stimulants, alpha-adrenergic agents, and other non-stimulant medications. Documenting these options helps you to remember to talk with families about them.

Possible results of no treatment: Make clear what the results of not treating might be. Sometimes it is serious, such as untreated psychosis or mania. Or it may be murkier, such as when a medication might be helpful but has less clear efficacy—in treating depression in children, response rates are often indistinguishable from placebo (Garland EJ et al, J Can Acad Child Adolesc Psychiatry 2016;25(1):4–10). We may attempt treatment anyway, hoping to help severe depression, but we should proactively discuss the possibility of limited efficacy with families to manage expectations and avoid surprises.

Discussing side effects: Review common problems that come up— issues with eating, sleeping, weight, etc. There is no clear need to discuss unusual side effects. But note the important things to watch for, such as extrapyramidal symptoms and syndromes with antipsychotics (tardive dyskinesia, akathisia, neuroleptic malignant syndrome), or Stevens-Johnson syndrome with lamotrigine (see: https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml).

FDA labeling: Child psychiatrists often prescribe outside of the FDA indications. Discuss this with families and patients (the latter as developmentally appropriate), and document the discussion. Ensure that you have reasonable evidence, record your rationale, and note that while the plan is considered experimental by FDA standards, you judge it to be safe based on use in other populations or situations.

Consent and assent: Note that parents sign consent for treatment, and children of about 7 and up may assent (agree) to treatment. Try to get the child on board in understanding that the medication is being used to help specific things. Listen to what the child says is helpful and, conversely, what the child does not like. This makes for a more effective treatment process. If you are dealing with a custody situation, pay attention to issues of shared medical decision-making. You often need both parents to sign off on the medication plan, except in certain emergency cases.

Comments, questions, and concerns: Here, note follow-up plans and additional aspects of treatment (eg, therapies, school liaison, and follow-up testing).

Affirmation of understanding and signature block: Families sign that they understand and commit to the plan, consent to the treatment, will work with you on it, and will read the package insert for the medication(s) involved.

Space for updates: I incorporate a flow sheet to add new trials, which is dated and initialed as the informed consent process develops.

CCPR Verdict: Informed consent is ongoing, not a one-time event. It’s a framework for care. The document can be a touchstone to focus follow-up care, reminding us to ask about the specifics of the clinical situation, effects of the current plan, and treatment options.
Child Psychiatry
KEYWORDS child_psychiatry free_articles practice_tools_and_tips
    Jfeder1
    Joshua Feder, MD

    Expanding Access to OCD Treatment

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Psychotropic Risks in Children and Adolescents, CCPR, May/June 2018
    Informed Consent: An Ongoing Process for Focused Care
    Embracing Conflict in the Consent Process
    Considerations When Prescribing Psychotropic Medications
    Metformin to Control Antipsychotic-Induced Weight Gain in Children
    Tips for Good Medication Practice
    Youth, Antidepressant Medications, and Type 2 Diabetes
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.